🤮 #Afflelou #krys

L’opticien Krys s’installe rue Chartraine - Site officiel de la Ville d’Évreux À la tête du magasin, Saïda Amar, forte de plus de vingt ans d’expérience dans l’optique, revendique une approche centrée sur l’accompagnement personnalisé. « Chaque client arrive avec une histoire et...

#Evreuxnormandie - Le Coup de Coeur de Willy #Colors dans le centre-ville d'#Évreux 🌈 : La rue Chartraine accueille une nouvelle enseigne : Krys, qui vient...
🌀 #Eure #EvreuxAutrement #Evreux #opticien #Krys #commercedecentreville #commerces #Optique #lunettes 🌀
www.evreux.fr?p=2574318&po...

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced

#KRYS Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/KRYS/krystal-biotec...

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis Krystal Biotech (NASDAQ: KRYS) announced an investor conference call and webcast on January 8, 2026 at 4:30 PM ET to present an interim clinical update from CORAL-1, its multi-center Phase 1 dose-escalation study of KB407 in patients with cystic fibrosis. The update will focus on data from the highest dose cohort and include molecular assessments of KB407 transduction and wild-type CFTR protein expression following inhaled administration.Live webcast access is provided and an archived recording will be available on the company’s Investors website for at least 30 days.

#KRYS Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

www.stocktitan.net/news/KRYS/krystal-biotec...

Don't forget to appreciate the artists who made this Friday special, go and like their art too!

Dêem um Like ao artista, vamos valorizar esses que fazem o Feralisextou especial!

www.deviantart.com/kaosmass95/a...

#Feraligatr #Pokemon #PokemonFanart #PokeArt #Krys #PokemonCrystal #GameBoy

IT'S FERALIFRIDAY, AN AMAZING WEEKEND FOR ALL OF YOU, MY FERALIFOLLOWERS❣️

FERALISEXTOU! DESEJO UMA SEMANA INCRÍVEL, E UM FINAL DE SEMANA DIVERTIDO PARA VOCÊS, MEUS FERALISEGUIDORES❣️

#Pokemon #PokemonLegendsZA #Feraligatr #Totodile #PokemonFanart #Mega #PokemonCrystal #Krys

#KRYS Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/KRYS/krystal-biotec...

Sexy Dance (feat. Krys) Fally Ipupa, Krys · Arsenal de belles mélodies · Song · 2009

🇺🇦 #NowPlaying on #KEXP's #Continent

Krys feat. Fally Ipupa:
🎵 Sexy Dance

#Krys #FallyIpupa

▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify

▶️ Song on #Spotify:

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 (HSV-1)

#KRYS Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

www.stocktitan.net/news/KRYS/krystal-biotec...

A feline sitting at table holding her glass licking her lips.

Art © Ellever-10
Krys Reinfield © ArcticBrightwater

#female #feline #sabertooth #tattoo #krys #KrysReinfield #arcticbrightwater #tipsy
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

Art © Ellever-10
Krys Reinfield © ArcticBrightwater

#female #feline #sabertooth #krys #KrysReinfield #arcticbrightwater #Ellever10
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

A mostly nude anthropomorphic feline is depicted wearing a bedsheet draped over her head. She is posed as a ghost, and her mouth is open in a 'boo' expression.

Art ©  KyraKawaguti
Krys Reinfield © ArcticBrightwater

#female #feline #sabertooth #tattoo #krys #KrysReinfield #arcticbrightwater
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

An anthropomorphic feline is depicted wearing a purple lingerie outfit and has a bedsheet draped over her head. She is posed as a ghost, and her mouth is open in a 'boo' expression.

Art ©  KyraKawaguti
Krys Reinfield © ArcticBrightwater

#female #feline #sabertooth #tattoo #krys #KrysReinfield #arcticbrightwater
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

Art © AGRIXXX

Krys Reinfield © ArcticBrightwater
Kaija © KaijaBurr

#female #feline #sabertooth #tattoo #krys #KrysReinfield #arcticbrightwater
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

An anthropomorphic feline is wrestling and choking an anthropomorphic bear in a wrestling arena.

Art © AGRIXXX

Krys Reinfield © ArcticBrightwater
Kaija © KaijaBurr

#female #feline #sabertooth #tattoo #krys #KrysReinfield #arcticbrightwater
Please do not roleplay, use, redistribute, image train, or edit any work in my gallery. Thank you ♡

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer Krystal Biotech (NASDAQ: KRYS) announced a strategic update for its oncology program KB707, focusing on the inhaled delivery method for treating non-small cell lung cancer (NSCLC). The company has secured an FDA End of Phase 2 meeting in October to discuss potential registration pathways for inhaled KB707.The decision follows promising clinical results presented at ASCO 2025, showing an objective response rate of 36% in heavily pre-treated NSCLC patients. The treatment demonstrated durability with median response and progression-free survival not yet reached. Importantly, inhaled KB707 showed a favorable safety profile with no Grade 4 or 5 adverse events.As part of this prioritization, Krystal has paused enrollment in the OPAL-1 study for intratumoral KB707 while continuing the KYANITE-1 study for inhaled KB707 in lung tumors.

#KRYS Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

www.stocktitan.net/news/KRYS/krystal-biotec...

Krys kneeling and with boobs so full of milk that the milk is just leaking and spurting out of them

wife...

#Krys makin milk..... 👀
#smuttysquid

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results Krystal Biotech (NASDAQ: KRYS) reported strong Q2 2025 financial results, highlighted by $96.0 million in VYJUVEK revenue and a robust cash position of $820.8 million. The company achieved significant milestones including VYJUVEK's approval in Japan for DEB treatment from birth, with $525.4 million in total revenue since launch in 3Q 2023.The quarter saw impressive performance metrics including 93% gross margin and 82% patient compliance. Net income reached $38.3 million ($1.33 per share), with planned European launches in Germany (Q3) and France (Q4). The company advanced multiple clinical programs across respiratory, ophthalmology, oncology, and aesthetics divisions, with key trial progressions in CF, AATD, corneal treatments, and solid tumors.

#KRYS Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/KRYS/krystal-biotec...

Krys sits, covered in cum, and steamy from a high intensity session as she edits a soundbyte with headphones on. In front of her, an audio Waveform titled uncroppedcumfart.wav plays through her headset

uncroppedcumfart.wav

making beats with #krys

#smuttysquid

Krys and Ron are engaging in sensual sillyness. Ron buries in Krys's sweaty musky ass, tongue diving her bodacious bits as she leans back into him, pulling down her shiny pants and gently teasing his bellend with a titty hangin out!

Cake for dinner

#Krys is the thinking person's power waifu

#smuttysquid #comm for @truemac.bsky.social (originally done december 2022!!)

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa Krystal Biotech (NASDAQ: KRYS) has received marketing authorization from Japan's Ministry of Health, Labour and Welfare for VYJUVEK®, marking a significant milestone as the first genetic medicine approved in Japan for treating dystrophic epidermolysis bullosa (DEB).The approval allows for flexible administration options, including home dosing and administration by patients or family members. VYJUVEK works by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression. The company expects to launch in Japan by the end of 2025, pending completion of reimbursement procedures.Clinical data supporting the approval included results from a Japanese open label extension study, where all four patients achieved full wound closure at six months, consistent with previous U.S. Phase 3 study results. The treatment has already received approvals in the United States (May 2023) and Europe (April 2025).

#KRYS Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

www.stocktitan.net/news/KRYS/krystal-biotec...

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté Jeune Aesthetics (NASDAQ: KRYS) announced positive Phase 1 results from the PEARL-2 study evaluating KB304 for treating décolleté wrinkles. The randomized, double-blind, placebo-controlled trial demonstrated significant aesthetic improvements in 19 subjects, with 100% of KB304-treated patients showing improvement at three months according to investigator assessments.The study showed substantial benefits across multiple skin attributes, including elasticity, crepiness, hydration, and radiance. 81.8% of KB304-treated subjects reported improved satisfaction with wrinkle appearance versus 14.3% for placebo. The safety profile was consistent with prior clinical experience, showing only mild-to-moderate adverse events.Following these positive results, Jeune plans to advance KB304 to Phase 2 development, targeting initiation in the first half of 2026 after FDA consultation.

#KRYS Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

www.stocktitan.net/news/KRYS/jeune-announce...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #JBHT 344.0x
2. #RLX 167.6x
3. #PPL 124.1x
4. #KRYS 35.8x
5. #GNW 18.8x

#OptionFlow #OptionsTrading #Trading

Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial Novel eye drop gene therapy KB801 enters Phase 1/2 trial for neurotrophic keratitis. Targeting 68,000-patient US market with breakthrough delivery system. See trial details.

#KRYS Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

www.stocktitan.net/news/KRYS/krystal-biotec...

#TMDX #PODD #VEEV #OPCH #INSP #BEAM #LFMD #CERT #KRYS #TEM #de58360b-9299-4682-bac3-d7906ea4ff35

Origin | Interest | Match

Krystal Biotech Announces First Quarter 2025 Financial and Operating Results VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular

#KRYS Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/KRYS/krystal-biotec...

European Commission Approves Breakthrough Gene Therapy VYJUVEK for Rare Skin Disease Treatment First corrective treatment for dystrophic epidermolysis bullosa approved across 30+ European countries. Includes unique at-home administration option. See launch timeline.

#KRYS Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

www.stocktitan.net/news/KRYS/krystal-biotec...

Le concert de #Krys était incroyable ! En fosse, l’expérience était magique: l’énergie !!!

As if viewed on a handheld camera, Krystal sits on a bed with her hands on her breasts, she's steaming presumably after a hot bath, and she is incredibly pregnant. Offscreen, ROI says: Gee Krys, your titties sure look fat and awesome today~! Krys responds: Othx ROI! I grew them myself!

As if viewed on a handheld camera, Krystal sits on a bed with her hands on her breasts, she's steaming presumably after a hot bath, and she is incredibly pregnant. Also her boobs are leaking milk!! Offscreen, ROI says: Gee Krys, your titties sure look fat and awesome today~! Krys responds: Othx ROI! I grew them myself!

i drew this in 2022!!
everyone put your hands together for the fav blue fox #krys !!!

#smuttysquid

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa Krystal Biotech (NASDAQ: KRYS) has received a positive recommendation from the European Medicines Agency's CHMP for VYJUVEK®, a treatment for dystrophic epidermolysis bullosa (DEB). The therapy targets patients with COL7A1 gene mutations from birth.The CHMP's recommendation supports VYJUVEK administration in clinical settings or at home, with trained patients or caregivers allowed to apply the treatment. The European Commission's final approval decision is expected in Q2 2025, covering EU member states, Iceland, Norway, and Liechtenstein.The recommendation is based on Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, published in Nature Medicine and the New England Journal of Medicine. The company plans to launch first in Germany mid-2025, followed by France later that year.

#KRYS Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

www.stocktitan.net/news/KRYS/krystal-biotec...